Blenoxane
(Bleomycin)ApprovedSmall molecule
Bristol-Myers SquibbBleomycin is a chemotherapy drug used to treat certain cancers, including testicular cancer, lymphoma, and squamous cell cancers. It works by damaging cancer cell DNA to stop them from growing.[2] Blenoxane is currently approved and in use across 17 indications[4].[1]
Blenoxane is one of 241 small molecule programs targeting Hemangioma. It is currently in Approved.
17
Indications
65
Total Trials
20
Active Trials
240
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbApproved
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma17 trials
Show 14 more trials
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00369681·51 enrolled
Germ Cell Tumor4 trials
Plantar Wart3 trials
The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts
Unknown status·—·Phase 4·NCT03477448·40 enrolled
Microneedling Alone Versus Microneedling Coupled With Either Bleomycin or 5flourouracil in the Treatment of Plantar Warts
Not yet recruiting·—·N/A·NCT07041749·60 enrolled
A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Approved·NCT07197541·200 enrolled
Hodgkin's Disease3 trials
Hodgkin Lymphoma3 trials
27 more indications
Chemotherapy2 trials
Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy
Withdrawn·—·Phase 2·NCT00918593·98 enrolled
Lymphatic Malformation2 trials
Venous malformation2 trials
Cancer2 trials
Classic Hodgkin Lymphoma1 trial
Vulvar Cancer1 trial
Hodgkins lymphoma1 trial
Brentuximab Vedotin1 trial
Glioblastoma Multiforme1 trial
Diffuse Large B-Cell Lymphoma1 trial
Brain Metastases1 trial
Electrochemotherapy as a Palliative Treatment for Brain Metastases
Terminated·—·Phase 1·NCT01322100·1 enrolled
Metastasis1 trial
Germ Cell Tumors1 trial
Vascular Malformations1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
BLENOXANE
NDA NDA050443
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Blenoxane drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Bleomycin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company